AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: David Ranii
Jun. 8--Lotronex, the GlaxoSmithKline drug for irritable bowel syndrome that has inspired ardent support from patients who say it changed their lives as well as withering attacks from critics who say it kills people, has made an unprecedented comeback.
Friday, the U.S. Food and Drug Administration approved a restricted marketing program for the drug, the first time the agency has ever permitted a company to sell a drug after it was withdrawn from the market because of safety concerns.
The decision is a victory for sufferers of irritable bowel syndrome who have been lobbying for Lotronex's return ever since GSK pulled it from the market in November 2000. The FDA requested the withdrawal in response to reports of five deaths and dozens of instances of serious health problems in people who took the drug.
Irritable bowel syndrome, or IBS, affects an estimated 18.5 million Americans. It causes lower abdominal pain and irregular bowel habits, including constipation and diarrhea so severe that it can disrupt every aspect of a person's life.